17 Capital Partners’s Edwards Lifesciences EW Stock Holding History

17 Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$804K	Buy	10,036 +3,325	+50%	+$274K	0.41%	87
2025 Q4	$572K	Buy	+6,711	New	+$551K	0.29%	103
2022 Q3	$339K	Hold	4,108	–	–	0.46%	66
2022 Q2	$391K	Hold	4,108	–	–	0.49%	65
2022 Q1	$484K	Hold	4,108	–	–	0.5%	67
2021 Q4	$532K	Hold	4,108	–	–	0.49%	68
2021 Q3	$465K	Buy	4,108 +25	+0.6%	+$2.85K	0.44%	70
2021 Q2	$423K	Buy	+4,083	New	+$385K	0.39%	74

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

17 Capital Partners's EW Position: Q1 2026 in Review

17 Capital Partners increased its Edwards Lifesciences (EW) stake by 50% in Q1 2026, buying an estimated $274K and bringing the position to 10,036 shares worth $804K. The position accounts for 0.41% of the portfolio, ranked #87.

17 Capital Partners first reported a position in EW in Q2 2021 and has held it in 8 quarters since. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.

17 Capital Partners held 10,036 shares of Edwards Lifesciences worth $804K as of Q1 2026.
17 Capital Partners bought 3,325 Edwards Lifesciences shares in Q1 2026, an estimated $274K.
Edwards Lifesciences made up 0.41% of 17 Capital Partners's portfolio in Q1 2026, its #87 holding.
17 Capital Partners first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 8 quarters since.
1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on 17 Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.